Skip to main
SKIN
SKIN logo

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Beauty Health is demonstrating a strong financial performance, with 4Q23 revenue reaching $96.8 million, surpassing both previous estimates and expectations from analysts. The company has shown a significant improvement in its average selling price (ASP) for systems, which increased approximately 20% quarter-over-quarter to $28.8K, reflecting a favorable shift in sales channels towards direct sales. Additionally, the positive revenue trends were primarily driven by strong consumer demand for consumables, indicating robust market traction for the company's product offerings.

Bears say

Beauty Health Co. has experienced a significant decline in new core delivery system placements, reporting 1,210 placements, which is over a 30% decrease both year-over-year and quarter-over-quarter, falling short of previous estimates. This deceleration is concerning, as new system placements are crucial for driving future consumables sales, which are integral to the company's profitability goals for 2024. Additionally, management's guidance for 1Q24 sales of $80 million and adjusted EBITDA of -$7.5 million is significantly below prior estimates, indicating potential challenges in achieving the projected full-year EBITDA target of over $40 million.

SKIN has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Buy based on their latest research and market trends.

According to 3 analysts, SKIN has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.